Bringing high-quality and high-added-valued medicines to patients around the world
At Towa International, we work to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.
Our
Ikigai
We contribute to people’s health
We are dedicated to people’s genuine smiles
Our
Activity
We research, develop, manufacture, and market complex generics
and value-added medicines for patients around the world.
1st Japanese
generic, value-added medicines, and OTC company in Europe.
+0M
in sales
+0
employees
+0
products
About
Us
Our journey begins in 1951 when Towa Pharmaceutical was founded in Osaka – a family-run pharmaceutical company that specializes in the manufacture of therapeutic solutions in Japan.
In 2020 Towa Pharmaceutical became international by adding Towa International business, and we became its major company who operates worldwide within a platform of an R&D center, innovative production capabilities, and direct commercial presence in Europe and the United States of America.
We are building a global business to provide patients around the world with high-quality and high added– value medicines and to support the sustainability of health systems.
Our story together
TOWA
PHARMACEUTICAL
TOWA
INTERNATIONAL
1951
Towa Pharmaceutical was originally founded as a family-run business
1989
Pensa originates from PPI expertise and a non-infringement formulation of Omeprazole
1992
Contruction of Martorelles (Barcelona) manufacturing and R&D facilities
1998
Osaka Research Center and Osaka Distribution Center are constructed at Osaka, Japan
2004
Towa was listed on Tokio’s stock exchange.
2022
Internationalization process entering South America and Middle East though licenses and strategic alliances.
International
presence
Our business
Towa US.
Breckenridge Pharmaceutical.
The US.
Breckenridge markets and distributes branded, high-quality, cost-effective generic pharmaceuticals in the United States, under an own-label distribution model.
We act as a trusted pharmaceutical partner, offering our development and manufacturing partners a unique opportunity to reach the US market.
Towa EU.
Towa Pharmaceutical.
Europe.
In 2022, we changed the name of our three commercial affiliates, being now: Towa Pharmaceutical.
We are still operating with our commercial brands, Pensa and ToLife, and planning to do a voluntary and slow transition for the benefit of our patients.
Towa 2B.
B2B.
Worldwide.
We operate worldwide, being present in more than 30 countries.
We want the largest partners in the world to contribute to high-value-added therapeutic solutions to improve people’s life.
Our presence
Towa International’s headquarters are situated in Barcelona, housing the R&D center, an innovative state-of-art center production facility, corporate services, and a sales team. We are also in Italy, Portugal, Germany, Sweden, and the US. From these locations, and through strategic alliances, we reach patients in more than 30 countries.